<SEC-DOCUMENT>0000950170-23-017842.txt : 20230504
<SEC-HEADER>0000950170-23-017842.hdr.sgml : 20230504
<ACCEPTANCE-DATETIME>20230504160643
ACCESSION NUMBER:		0000950170-23-017842
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20230503
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230504
DATE AS OF CHANGE:		20230504

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			STAAR SURGICAL CO
		CENTRAL INDEX KEY:			0000718937
		STANDARD INDUSTRIAL CLASSIFICATION:	OPHTHALMIC GOODS [3851]
		IRS NUMBER:				953797439
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1230

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-11634
		FILM NUMBER:		23888658

	BUSINESS ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016
		BUSINESS PHONE:		6263037902

	MAIL ADDRESS:	
		STREET 1:		1911 WALKER AVE
		CITY:			MONROVIA
		STATE:			CA
		ZIP:			91016

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	STAAR SURGICAL COMPANY
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>staa-20230503.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2023-05-04T15:18:43.7685+00:00 --><!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:staa="http://www.staar.com/20230503" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_64de1f4b-095f-48e3-b685-4a8f2925b0a8" name="dei:EntityCentralIndexKey" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e">0000718937</ix:nonNumeric><ix:nonNumeric id="F_14d752fb-b279-4f44-bc42-953f27389b5e" name="dei:AmendmentFlag" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" format="ixt:booleanfalse">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="staa-20230503.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_493298ae-fd11-4831-979d-29b516e5725e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000718937</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-03</xbrli:startDate><xbrli:endDate>2023-05-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="margin-left:37.213%;text-indent:0.0%;font-size:10.0pt;margin-top:3.9pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:34.417%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">UNITED STATES</span></p>
  <p style="margin-left:14.6%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:11.833%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="margin-left:37.187%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:34.954%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">WASHINGTON, DC 20549</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">FORM </span><span style="font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_289f05e2-2dd7-46d4-a16d-0d9ca1d67a74" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:18.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1pt solid;margin-right:40.0%;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">CURRENT REPORT</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:32.987%;text-indent:0.036%;font-size:10.0pt;margin-top:1.45pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:30.213%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:16.96%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:14.731%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Date of report (Date of earliest event reported):  </span><span style="font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_ca1b4a79-b72f-496c-b5de-4df05f7f2f24" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 3, 2023</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.5pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:30.187%;text-indent:0.0%;font-size:10.0pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.019%;text-align:center;"><span style="font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_9d3cfa91-fdf1-4465-898b-3a62234a8a60" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAAR Surgical Co</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">mpany</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:30.133%;text-indent:0.0%;font-size:10.0pt;margin-top:1.6pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:28.0%;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Exact Name of Registrant as Specified in Charter)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.8pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:11.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">	</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f24eb8c8-ecc4-4997-8af5-7e980d1d56cd" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f0ec8e06-0eb0-4cc6-9c4a-51614a475d69" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">0-11634</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_50164d6d-eacc-4cf1-a9ac-19a4f9bcc1bf" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">95-3797439</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(State or Other Jurisdiction</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(IRS Employer</span></p><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_4c6eb8b1-df80-4596-b6d3-ba7939cb738b" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">25651 Atlantic Ocean Drive</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_c5ec6a8c-42df-4385-8761-384dcbad201f" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Lake Forest</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_6c23b54d-804b-4774-835b-5154a090604e" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_b826b5a4-3dbd-4954-99a9-ae8484728642" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">92630</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.1in;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:4.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="text-indent:0.0pt;font-size:7.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">Registrant&#x2019;s Telephone Number, Including Area Code: </span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_dc80706e-b08c-402b-a28a-8dbbcbbcfdb8" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">626</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">-</span><span style="font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_757df7b0-7edd-48a2-b533-5fab5b56cfc2" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">303-7902</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Not Applicable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:10.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;"> </span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:1.65pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.926%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">see </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">General Instruction A.2. below):</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_ba7abf3f-3f0a-4710-bb4c-46ac842a1121" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_150c75e4-0398-4f16-b174-e9e1710e0e9f" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_c3db273f-0e51-4ec1-a868-f2de7ae48196" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_ed7443be-7fb0-4909-afca-0375a4ab6418" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:96.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
    <td style="width:33.333%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Title of each class</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_8c3d9f71-a32f-4610-b2e3-be01b91e6a54" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Common</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_7e0debd2-b2f4-475a-b0d4-6abd2f65053d" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAA</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;padding-left:0.075in;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;"><ix:nonNumeric id="F_f8cdc060-094c-4890-bfbc-e58cb1a8a1a4" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">NASDAQ</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.593%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1 933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</span></p>
  <p style="margin-left:0.933%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Emerging growth company </span><span style="font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;"><ix:nonNumeric id="F_06f37a7d-594a-4ea4-9199-a63f90cbf88a" contextRef="C_493298ae-fd11-4831-979d-29b516e5725e" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.35pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.5pt;font-family:&quot;Calibri&quot;, sans-serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Segoe UI Symbol&quot;, sans-serif;min-width:fit-content;">&#9744;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="margin-left:0.92%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:2.519%;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">On May 3, 2023, the Company held a conference call to discuss the financial results for the quarter ended March 31, 2023.  A transcript of the conference call is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The information furnished herewith pursuant to Item 7.01 of this Current Report, including Exhibit 99.1, shall not be deemed to be &#x201c;filed&#x201d; for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), or otherwise subject to the liabilities of that section. The information in Item 7.01 of this Current Report, and Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.999%;"></td>
    <td style="width:1.4%;"></td>
    <td style="width:0.999%;"></td>
    <td style="width:82.602%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="staa-ex99_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Transcript of conference call of the Company held on May 3, 2023.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">104</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">SIGNATURE</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:15.0%;"></td>
    <td style="width:3.2%;"></td>
    <td style="width:81.8%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">STAAR Surgical Company</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">May 4, 2023</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">/s/ Tom Frinzi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Thomas G. Frinzi</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>staa-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,110,186,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">C O R P O R A T E  P A R T I C I P A N T S</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Brian</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Moore</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">F.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Williams</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">G.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Frinzi</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,110,186,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">C O N F E R E N C E  C A L L  P A R T I C I P A N T S</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">AnthonyCharlesPetrone</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MizuhoSecuritiesUSALLC,ResearchDivision-MD&amp;SeniorMedicalDevices,DiagnosticsandTherapeuticsEquityResearchAnalyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Bruce</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">David</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Jackson</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">The Benchmark Company, LLC, Research Division - Senior Equity Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">David</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Joshua</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Saxon</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Needham &amp; Company, LLC, Research Division - Senior Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Harrison</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Clark</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Parsons</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Stephens Inc., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">James</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Philip</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Sidoti</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Sidoti &amp; Company, LLC - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">John</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Edward</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Young</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Canaccord Genuity Corp., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Malgorzata</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Maria</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Kaczor</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Andrew</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">William Blair &amp; Company L.L.C., Research Division - Partner &amp; Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Ron</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Feiner</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Oppenheimer &amp; Co. Inc., Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Samuel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Durno</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">BTIG, LLC, Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">M.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Stephan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Xuyang</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Li</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Jefferies LLC, Research Division - Equity Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,110,186,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">P R E S E N T A T I O N</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Good day, ladies and gentlemen. Thank you for standing by. Welcome to the STAAR Surgical First Quarter Financial Results Conference Call. (Operator Instructions) This call is being recorded today, Wednesday, May 3, 2023. At this time, I would like to turn the conference over to Mr. Brian Moore, Vice President, Investor, Media Relations and Corporate Development for STAAR Surgical. Please go ahead.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Brian Moore </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - VP of Investor, Media Relations &amp; Corporate Development</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thank you, operator, and good afternoon, everyone. Thank you for joining us on the STAAR Surgical conference call this afternoon to discuss the company's financial results for the first quarter ended March 31, 2023. On the call today are Tom Frinzi, President and Chief Executive Officer; and Patrick Williams, Chief Financial Officer.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">The press release of our first quarter results was issued just after 4:00 p.m. Eastern Time and is now available on STAAR's website at www.staar.com.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs and prospects. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the safe harbor statement in today's press release as well as STAAR's public periodic filings with the SEC. Except as required by law, STAAR assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">2</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">In addition, to supplement the GAAP numbers, we have provided non-GAAP adjusted net income and adjusted earnings per share and sales in constant currency. We believe that these non-GAAP numbers provide meaningful supplemental information and are helpful in assessing our historical and future performance. A table reconciling the GAAP information to the non-GAAP information is included in today's press release. For brevity, all references to growth rates on today's call refer to year-over-year growth unless otherwise stated. Following our prepared remarks, we will open the line to questions from publishing analysts. We ask analysts limit themselves to 2 initial questions, then re-queue with any follow-ups. We thank everyone in advance for their cooperation with this process. And with that, I would now like to turn the call over to Tom Frinzi, President and CEO of STAAR.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thank you, Brian. Good afternoon, everyone, and thank you for joining us on today's call. The first quarter results we reported today illustrate continuing market share gains for our EVO ICL family of lenses even as total refractive surgery procedure volumes are challenged or declining in many markets. Global ICL growth in the first quarter, up 20% for both sales and units was broad-based across APAC, EMEA and the United States. These strong results and the further momentum that we are experiencing globally confirm our confidence in the year. We are, therefore, raising our fiscal 2023 net sales outlook to approximately $348 million, which includes the approximate $3 million in other product sales we reported for Q1. Our raised outlook represents 28% ICL sales growth.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">For the first quarter, global ICL sales of $70.6 million were $3.6 million above the high end of our USD65 million to USD67 million outlook. Results were driven by a restorative quarter for ICL procedures in China, which commenced in mid-January and has continued unabated. ICL unit growth in China was 20% for the first quarter of 2023. China indeed is back. And as a result, ICL procedures in China are certainly back. To deliver the strong results in China, our team hosted surgeon training events, academic conferences and advanced practice development and consumer marketing activities, often in partnership with our surgeon customers. One live stream surgery training was attended by over 1,800 doctors and clinical staff. Another young surgeon conference was attended by over 1,300 doctors and residents and the conference in collaboration with the key university hospital account was attended by over 3,800 ophthalmic doctors and clinical staff.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Consumer marketing in-country was diversified across digital content channels and emphasized the sharp, clear and high-quality vision provided by EVO-ICL as well as our custom Toric lenses specifically developed for myopia with astigmatism. One marketing program with influencers received over 1 million views during the quarter. Two weeks ago, we hosted leadership from our largest customer in China, IRI Hospital at our Lake Forest, California headquarters. And during that meeting, IRI's leadership reinforced the importance of ICL to their overall growth strategy globally.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">As a region, overall, APAC delivered solid performance, up 19% in units and 20% in sales for the first quarter of 2023. In the United States, ICL units grew 78% for the first quarter, well ahead of industry volumes in the U.S., which the Refractive Surgery Council reported declined 9.1%. Sequentially, our U.S. sales in the first quarter were relatively flat. However, we are coming off a strong March and remain confident in our Q2 projections and a doubling of sales in the U.S. for the full year.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">During the first quarter, we executed on the planned infrastructure additions to our U.S. commercial organization, which we believe are important to driving growth and better serving our customers. The number of account executives, clinical application specialists and practice development personnel across our U.S. commercial organization has markedly increased and will continue to grow in targeted markets when appropriate. We expect our new team additions will become productive in the second half of 2023 and even more so beyond that. This month, we entered the eighth month of our direct-to-consumer supported EVO launch in the U.S. Our DTC marketing efforts, which target potential patients, primarily ages 21 to 35, are working to build the awareness and the funnel of future ICL patients.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">In the first quarter of 2023, we saw a 402% increase in visits to our U.S. doctor finder. We anticipate that these visitors will begin their journey of discovery, learning more about EVO and the ICL procedure for their visual freedom selection. I would like to share with you an e-mail from one of our customers who is a surgeon CEO of a multicenter chain of U.S. clinics. The email reads as follows, and I quote, &#34;I just wanted to let you and your team know that STAAR's marketing seems to be really paying off with EVO ICL. There's a lot more consumer awareness. For the surgeon and staff, it is less of a sell and has become quite easy to convert patients to surgery. Our volume is still relatively low, but I think it is because we are still targeting the higher miles for ICL, but our surgeons and staff are getting more comfortable with EVO ICL. We have reduced the number of appointments in patient anxiety by eliminating the need for laser peripheral iridotomy. This gives us comfort to reduce the level of myopia we are comfortable treating with ICL. Our plan is to make our website more EVO ICL friendly. Thanks to STAAR for having the foresight to do effective DTC marketing, thanks to your whole STAAR crew for being forward thinking and putting patients and docs first.&#34;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">3</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Another doctor, a young surgeon based in California, has increased his ICL utilization 6x over the past year to approximately 12% of his practices, procedure mix and tells me that he expects to move his minus 8 diopter cutoff even lower. This surgeon told me he expects to see ICL gain significant market share in the coming year. The anecdotes I just shared are just 2 examples that we are building the market for EVO ICL in the U.S. New and exciting influencer in customer co-marketing partnerships in the U.S. have or will soon be finalized. These investments are budgeted and consistent with the investments we've talked with you about on our last call, which Patrick will also cover shortly.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Overall, based on my decades of experience in ophthalmology and my knowledge of our EVO ICL launch status, I'm quite pleased with where we are at this point in time. I'm confident that awareness, adoption and selection by surgeons and patients will continue to accelerate in the U.S.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Turning to our EMEA region. ICL units were up 18% in the first quarter, with sales up 10%, which were impacted by currency headwinds. 5 of the 6 major regions we track in EMEA had positive growth in the first quarter as compared to just 2 of 6 regions in the fourth quarter of 2022. We saw standout growth in European hybrid markets where we have made investments. As a reminder, STAAR invested in its first European hybrid market in 2020 in the Benelux and then Italy and France in 2021. These hybrid markets have consistently outperformed our pure European distributor markets. For example, in the first quarter of 2023, we saw year-over-year ICL unit growth in the Benelux, up 34%, France, up 20%; and Italy, up 45%.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">The STAAR team globally is focused on executing against the targeted priorities that are important for our growth and to our customers and shareholders. In March, we added 2 highly regarded ophthalmic leaders to our team, Warren Foust as Chief Operating Officer; and Dr. Magda Michna as Chief Regulatory Clinical and Medical Affairs Officer. We look forward to the contributions we are confident each will make for STAAR, our customers and patients.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">The big picture growth drivers for our business remain highly favorable. First, the number of people with myopia continues to grow, which further increases our already large addressable market globally. Millions of contact lens wearers stop wearing contacts every year due to intolerance, discomfort, hassle and the like, and many of these former contact lens wearers have the ability to pay for EVO ICL. Second, we have an EVO procedure that offers surgeons favorable economics and profitability. And third, we have a great product that many patients have determined is a preferable solution, which they have chosen to break free from contacts and eyeglasses.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">In early April, we completed a customer survey with just over 900 responses from our surgeon customers globally. In response to this statement, I am satisfied with STAAR Surgical product quality and clinical outcomes, 99% of over 300 China surgeon customer respondents agreed. In the U.S., 100% of approximately 100 U.S. surgeon customers responding agreed with the statement, I am satisfied with STAAR surgical product quality and clinical outcomes. EVO ICL is the real deal when surgeons and patients are exposed to EVO, they overwhelmingly agree. Our focus is to make EVO the first choice for doctors and patients seeking visual freedom. We're confident we'll continue to drive faster and faster growth as awareness of EVO continues to rise. As I have said on many occasions, the time for EVO is now. Patrick?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thank you, Tom, and good afternoon, everyone. Total net sales for Q1 2023 were $72.5 million, up 16% as compared to the $63.2 million of net sales in Q1 2022 and up 15% on a sequential basis from Q4 2022 net sales of $64 million. The year-over-year increase in net sales was attributable to a 20% increase in ICL sales, partially offset by a 36% decrease in other product sales. ICL sales of $70.6 million represented 96% of total company net sales for the first quarter as compared to 93% of total company net sales in the year ago quarter. Other product sales were $2.9 million for the first quarter. We continue to expect other product sales will represent a smaller and smaller percentage of net sales as we move through fiscal 2023 and take our support of the noncore cataract IOL business.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Gross profit for Q1 2023 was $57.6 million or 78.3% of net sales as compared to gross profit of $49.3 million or 77.9% of net sales for Q1 2022 and $49.8 million or 77.7% of net sales for Q4 of 2022. The 40 basis point increase in gross margin as compared to Q1 2022 is primarily due to geographic and product mix, partially offset by increased period costs associated with manufacturing projects. The 60 basis point sequential increase in gross margins from the fourth quarter is due to the higher ICL sales mix in Q1 2023 and geographic mix. For fiscal 2023, we continue to expect gross margin will be approximately 80% for the full year and each quarter.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">4</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Moving down the income statement. Total operating expenses for Q1 2023 were $54.8 million as compared to $37.2 million in Q1 2022 and $48.8 million for Q4 2022. Taking a closer look at operating expenses. Total operating expenses for Q1 2023 were consistent with our plans, though we did have some expenses which we had anticipated to be sales and marketing that ended up being booked in G&amp;A for Q1 and will continue moving forward. G&amp;A expense for Q1 2023 was $18.1 million compared to $11.9 million for Q1 2022 and $14.8 million for Q4 2022. The year-over-year increase in G&amp;A is due to increased compensation-related expenses, including a $1.5 million severance expense related to our IOL business in Japan, outside services and increased facilities cost. The sequential increase from Q4 2022 was due to increased compensation-related expenses, severance expenses related to our IOL business and increased outside services.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">For fiscal 2023, we now expect G&amp;A expense will be approximately $19 million per quarter. The increase from our prior outlook primarily relates to higher stock-based compensation and additional executive hires. Selling and marketing expense was $26.4 million for Q1 2023 compared to $17.3 million for Q1 2022 and $24.2 million for Q4 of 2022. The increase in selling and marketing expense from the prior year was due to increased advertising and promotional expenses, compensation-related expenses and trade shows and meetings. The sequential increase in selling and marketing expense was due to increased advertising and promotional expenses and compensation-related expenses. We continue to expect selling and marketing expense will be approximately $33 million for Q2 and each quarter for the balance of the year.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Research and development expense was $10.3 million in Q1 2023 compared to $7.9 million for Q1 2022 and $9.8 million for Q4 2022. The year-over-year increase in R&amp;D is due to increased compensation-related expenses and the U.S. EVO post-approval clinical trial expenses associated with the 3-year study. The sequential increase in R&amp;D is primarily due to increased compensation-related expenses. For fiscal 2023, we continue to expect R&amp;D expense will be approximately $11 million for each quarter.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operating income in Q1 2023 was $2.8 million or 3.8% of net sales as compared to $12.1 million or 19.1% of net sales for Q1 2022. We anticipate other income will be approximately $1 million per quarter for the balance of the year. Due to the aforementioned growth investments and increase in stock-based compensation, we now anticipate operating margin for the fiscal year 2023 will be approximately 10% at the middle of the range of our 5-year average. STAAR initially achieved positive annual operating margin and GAAP profitability in 2018, and we remain proud of our 5-year track record of profitability and cash generation, which we expect to continue in 2023 and is rare for a high-growth medical device company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Net income in Q1 2023 was $2.7 million or $0.05 per diluted share compared to net income of $9.6 million or $0.19 per diluted share in Q1 2022. On a non-GAAP basis, adjusted net income for Q1 2023 was $8.7 million or $0.18 per diluted share compared to adjusted net income of $14.4 million or $0.29 per diluted share in Q1 2022. A table reconciling the GAAP information to the non-GAAP information is included in today's financial release. For fiscal 2023, we continue to expect our effective tax rate will be approximately 25% to 30%, subject to no significant change in our valuation allowance. Turning now to our balance sheet. Our cash, cash equivalents and investments available for sale as of March 31, 2023, totaled $217.3 million as compared to $225.5 million at the end of the fourth quarter of 2022. The decrease in overall cash is due to the timing of annual compensation payouts that occurred in the first quarter. We continue to expect we will invest approximately $26 million in property and equipment. We also anticipate generating positive cash from operations for the balance of the year and ending fiscal 2023 with a higher cash balance in fiscal 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">As Tom mentioned earlier, we today raised our net sales outlook from $340 million to approximately $348 million for fiscal 2023, including approximately $345 million of ICL sales and an approximate $30 million U.S. ICL sales contribution. For Q2, we expect total ICL sales to be approximately $93 million, including sequential sales growth in China and a U.S. sales of approximately $5.5 million. We anticipate generating approximately 47% of our fiscal 2023 ICL sales outlook in the first half of the year and 53% in the second half of the year. Finally, this Friday, May 5, STAAR will host a surgeon lunch and panel during the American Society of Cataract and Refractive Surgery, ASCRS conference in San Diego. Please reach out to Brian Moore in Investor Relations if you would like to attend. STAAR will also be participating in the Benchmark Company Virtual Healthcare Conference and Barclays Southern California Investor Bus Tour both on May 23, the William Blair Annual Growth Conference in Chicago on June 6 and the Sidoti &amp; Company Virtual Investor Conference on June 14. This concludes our prepared remarks. Operator, we are now ready to take questions.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">5</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,110,186,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">QUESTIONS AND ANSWERS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">(Operator Instructions) Our first question for today comes from Anthony Petrone from Mizuho Group.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Anthony Charles Petrone </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Mizuho Securities USA LLC, Research Division - MD &amp; Senior Medical Devices, Diagnostics and Therapeutics Equity</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">And congratulations here on a strong first quarter result. Maybe Tom, I'll start with just the performance in China, obviously, describing it as back to normalized levels. A couple of follow-ups here would be, one, as we look into the seasonal peak, the normal seasonal peak, which would be 2Q and 3Q, how does it play out this year versus prior years? Is there any backlog that's going to be also in that number? And then I'll have a follow-up for Patrick.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">No, Anthony, good to hear from you, and thank you for the question. China is indeed back and we (technical difficulty) Q2 and Q3 being equally as strong. So as we enter into the high season, we're poised for a good run in China.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Anthony Charles Petrone </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Mizuho Securities USA LLC, Research Division - MD &amp; Senior Medical Devices, Diagnostics and Therapeutics Equity Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Excellent. And maybe just a quick one, if I could sneak it in there. Can you provide maybe the data on where ICL is as a percent of total refractive in China and maybe the aspirational target? And then the quick one for Patrick would be just the sales and marketing expense ramp this year was actually a little bit lower than we expected in 1Q. Just wondering how we should be thinking about it as the year progresses? Again, thanks and congratulations.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Sure. From a market share point of view, again, I think it's a moving target as we look to kind of confirm the number of refractive procedures, but I think we're comfortable that we're around 20% and growing.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">And then, Anthony, on my side, as per my prepared comments, we did have some expenses that we thought were going to be in sales and marketing when we gave the original guidance back in late February. We ended up booking those in G&amp;A. We also saw a slight increase in stock-based compensation. And so as I said, we're at about $33 million a quarter in absolute dollars for sales and marketing, and that what you'll see in Q2, Q3 and Q4. And so I think if you guys go back and reference to the prepared remarks, it should get the models very much in line.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Margaret Kaczor from William Blair.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">6</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Malgorzata Maria Kaczor Andrew </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- William Blair &amp; Company L.L.C., Research Division - Partner &amp; Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I wanted to start on guidance, if I could, and specifically on the U.S. side. So first, can you confirm the Q1 number being maybe close to $4.5 million, if it's flat sequentially? And then maybe you're up, it sounds like maybe $1 million sequentially in Q2 to $5.5 million. And I think you also referenced </font><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">6 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">maybe doubling by the end of the year, which gets me to about $9 million. So I just wanted to walk through that and make sure that I'm thinking about that correctly. And if you could provide any drivers around that, that would be useful.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. Sure. Thanks, Margaret, for the question. I'll let Patrick add his color as well. But your assumptions are correct in both what we think will happen in Q2 where Q1 was, and we remain confident that we'll double our business in the U.S. for the entire year 2023. we're encouraged by some of the metrics we look at, such as Doc Finder visits continue to go up in Q1, they were up over 400%. And we continue to see very good conversions on a day-to-day basis of doctors committing more and more of their total refractive procedures to EVO ICL.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Malgorzata Maria Kaczor Andrew </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- William Blair &amp; Company L.L.C., Research Division - Partner &amp; Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. Great. I appreciate that. And so maybe going a little bit deeper, right, on the U.S. side. I really appreciate the additional examples you provided in terms of a few calls on accounts and going down on the diopter curve. We've heard the same. But maybe, Tom, you could speak to kind of the most important or maybe even most successful practice development initiatives for the next few quarters? And I guess, when do you expect them to have a more material impact on utilization, particularly in those borderline EVO accounts?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. Sure. Margaret, as you know, change takes time, and we're seeing that in the U.S. but we're confident as we have made the investment in practice development and adding headcount and quota-carrying salespeople and clinical labs people, we're starting to see that bear fruit. And I can tell you almost on a weekly basis, I get calls from end users that are really pleased with their outcomes. They're continuing to push the diopter trend down. They're continuing to see brand awareness, people coming in, asking for EVO. So I think as we continue to monitor those, I remain very confident that each month, we're cracking the code more and more, and we remain very optimistic and confident that the U.S. is going to be where we want it to be.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Ryan Zimmerman of BTIG.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Samuel Durno </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- BTIG, LLC, Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">This is Sam on for Ryan. This one is on the 2023 operating margin guidance. You brought down operating margin expectations to 10%, but have also previously commented that spend will ramp into 2024. And right now, the Street is sitting at around 17.8% operating margins in 2024. I know you're not going to guide to 2024, but what are your thoughts on that 2024 Street consensus operating margin expectations? Do you think it's too high or too low given the spend in the U.S.? And I have a follow-up, too.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">7</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Sure. Yes, we're not going to comment, as you said, on 2024. We'll take a look as we continue to move through the quarter to see if we want to give some color as we move through this year and going into 2024. But as I mentioned, the primary driver was a noncash adjustment on the operating income, which was stock-based compensation. And so some of the other metrics that we look at internally, and I know a lot of the Street does as well, is what are we doing with op cash flow, free cash flow and certainly more of an adjusted EBITDA type number. And when I look at those, I'm very satisfied with where we're going, and we'll hold off on anything going into 2024 now. But we want to make sure that we're investing appropriately and being able to grow the U.S. commercial specifically. But honestly, the 95% of the other revenue across the world where we still have very low market share.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Samuel Durno </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- BTIG, LLC, Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">That's really helpful. Then as we look ahead for the remainder of 2023 and into 2024, how are you thinking about the impact of competition with the development of some domestic ICL companies in China?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. Sam, thanks for the question. Again, we really don't see competitive forces impacting our ability to continue to grow in China. I think 2 million implants sold worldwide, the safety, the efficacy of our technology has been well established, and we see that continuing to move forward unabated.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">And just to clarify, we're clear, I heard you say domestic. So I want to make sure if you were talking China or the U.S., but we are a PMA device. And so if anyone is going to do something here in the U.S., there's a long road to go as well as high investment dollars on that. So to be clear.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Bill Plovanic from Canaccord.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">John Edward Young </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Canaccord Genuity Corp., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">It's John on for Bill. I'll probably circle back to the U.S. where a lot of the focus is, it was a little bit lighter than the original guidance you had put out last quarter. And just a little bit more color on what you saw in the quarter. I know you said you saw a strong March, but can you talk a little bit about any productivity gains you're seeing? And how many of the planned 10 reps you had mentioned on the last call were hired? And just what do you expect for productivity out of those 10 hires?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. No, appreciate the call. And certainly, we have filled, I think, about 90% of those job openings that we have posted and talked about in previous calls, and we feel good about the quality of the people we've attracted and I think as we've said previously, it will take a quarter or 2 for those people to be very productive. So we feel good about the second half of the year. I think March was a strong month. April, we continue to see conversions happening, which gives us confidence in where we think Q2 will be and the fact that we reiterated that we believe we will double our business for the year in 2023. So again, in my years of being in this ophthalmic business, when you're creating a market and growing the market, it takes time. And quite frankly, we're right where we need to be. When you think about it, even though we were approved a year ago, we're really only about 6 to 7 months into our launch mode, when we really started to gear up our direct-to-consumer spend and creating brand awareness, increasing our infrastructure. So when you look at it from that viewpoint or that context, I think we're right where we need to be. And I feel very confident, as we keep growing month to month to month, we're right where we need to be, and we remain confident that the U.S. is growing at the rate it should be. Put that in further context, when you think about where we were in China back in 2016, we're growing at a rate in the U.S. greater than we were in China at a similar point in time. So again, another reason for being confident.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">8</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">John Edward Young </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Canaccord Genuity Corp., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Great. And just maybe to go a bit deeper into that strategy. Can you talk a little bit about any context around KOL engagement, which I know is a new focus for you, Tom. And then also just the new account versus go deep strategy and just how many surgeons today are trained?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Surgeons trained today are approaching, I think, 650 to 700 in that range. But as I said, we're more focused on going deeper than wider. Obviously, demand is going to be there. We'll certify new surgeons as that demand comes in. But we're really trying to concentrate on ensuring the surgeons that are already certified to do EVO ICL are surrounded with practice development support, clinical application support and quota carrying sales support to ensure they really are reducing this into the fabric of their practice and moving towards being the first choice when it comes to patients seeking visual freedom. We're not there. That's our aspirational goal, but we think we have the people, the programs and the process to get us there.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Yang Li of Jefferies.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Xuyang Li </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Jefferies LLC, Research Division - Equity Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">All right. Great. Maybe first one for Tom, just on the quote in the press release about EVO increasingly becoming a patient's first choice. Where are you seeing that? Is there an inflection point in terms of patient awareness or surgeon experience?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Well, I mean, thank you for the question, but I would say the fact that we're growing, we're up 70-plus percent year-over-year suggests that more and more patients are walking in the door and more and more docs are starting to convert. As I said, our aspirational goal is to be the first choice. We're not there yet. The inertia of LASIK is real. Laser vision correction has been around a while. and EVO is very early in its launch phase in this particular market in the U.S., but as previously stated, I think we're right where we need to be. And I remain confident, as previously stated, that we're right where we need to be. We're growing. We have momentum, and we really feel good about the U.S. growth.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">And I'll just add, we're about to go to ASCRS here, and we're going to be doing a surgeon panel there on Friday, which we talked about. And I think people are going to be excited to hear the takeaways from that, and you're going to start hearing a lot more doctors talk about exactly what you just asked, Yang, which is that they're thinking EVO first when a patient walks in the door asking for refractive surgery.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Xuyang Li </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Jefferies LLC, Research Division - Equity Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. Great. Yes. Looking forward to that. I'll be there. Maybe for the follow-up for Patrick. I guess, it's been a little bit more than a year since the U.S. approval. Just high level, how do you think the U.S. launch is going relative to your expectations? What's going better than expected? Or what's been a little bit more challenging than expected?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">9</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. I think, Tom hit a nail on the head, right, whenever you're trying to launch into a new market, you learn as you go along. And I think what you heard in the prepared comments now is a definite focus from Tom on voice of the customer and listening to that and trying to figure out what are those things that we need to knock down in order to make EVO the first choice. And so I'm very pleased with where we're at. We're better today than we were yesterday and certainly a year ago, and we're feeling really good of how we're starting off and excited about how the year will end up.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from David Saxon of Needham.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">David Joshua Saxon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Needham &amp; Company, LLC, Research Division - Senior Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Congrats on the really strong quarter. Maybe I'll start with one on the U.S. I mean, by my math, I think you're tracking right around 3% volume share. That's for the whole market. So I wanted to ask, is that what you're seeing internally? And then since you're taking the approach of going deep versus wide. Can you talk about the share ramp you see once you do get into an account?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Look, I would say that the goal I put out for the team, let's put it that way, is I think we should going into accounts, thinking we should earn our way to 50% of their total refractive procedure volume. Are we there today? No, absolutely not. Do we have practices that are approaching 20. The 25% of the refractive procedures are EVO ICL? Yes. And we're continuing to grow those types of practices. But as I said, when you're creating a market, when you're changing the market, when you're moving the inertia of LASIK, it takes time. And I think that this EVO launch is going to be no different. But I'm not discouraged at all by anything we're seeing, quite frankly, just the opposite I'm encouraged is I've had dinner meetings and phone calls with KOLs across the country. They're excited about what STAAR is doing and how EVO is performing.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">David Joshua Saxon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Needham &amp; Company, LLC, Research Division - Senior Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. That's helpful.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Let me just make one final comment for you. As a further testimony to that, our top 30 customers that we stay very close to are up 2x year-over-year. So again, we're seeing the kind of growth we want to see, and it keeps us feeling very bullish about the future.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">David Joshua Saxon </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Needham &amp; Company, LLC, Research Division - Senior Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. That's superhelpful. And then in the script, I think you talked about in Europe, you're seeing hybrid markets grow faster than distributor markets. So I wanted to ask how big of a growth opportunity is that to get more of your distributed markets converted to hybrid markets? And then maybe I'll tack on another one for Europe. Maybe just talk about the Viva launch, I think that was launched in September. So how is that going? And then thoughts on the time line for Viva getting into the U.S.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">10</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. Look, I think hybrid versus distributor, it's depending on the market and what we find. We're trying to be responsive to what moves the market the most. As we said in the prepared remarks, we're very pleased with what we've seen in Benelux and France and Italy, it doesn't mean that our distributor markets aren't performing, but we're very pleased with those 3 in particular, and that's where we've put some investment dollars to work, and it seems to be bearing fruit. I'm glad you mentioned, EMEA, because, again, I get that a lot of you were focused on the U.S. But quite frankly, we're a global company, and we're continuing to grow around the world. China, Asia Pac, in general, had a great quarter. Europe had a great quarter. The U.S. is continuing to grow, and I think it speaks to the excitement of EVO around the world.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Steven Lichtman from Oppenheimer.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Ron Feiner </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Oppenheimer &amp; Co. Inc., Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">This is Ron on for Steve. I wanted to ask on China, continuing to see really great growth. How long do you guys think this high growth can continue? I mean, obviously, China is a very big part of STAAR's revenue. So how far do you guys think the refractive market over there is going to shift in your favor? And do you have any targets and trends like that in other countries that would be similar?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I think the runway is big in China. We're well established there. But boy, we have great opportunity for continued growth. China is back, as we said earlier, all indications are, it's back to normal levels. We're seeing very good in-country demand. So the sky is the limit.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">And I'll just add on that one. I think one of the big things that we've talked a little earlier is what the total addressable market size is and we are now talking more along the lines of a 1.5 million to 1.6 million [eyes]. We just had our largest customer here, the IR Hospital Group, as Tom talked about in his prepared remarks. They supported that. In fact, we're starting to hear numbers that are even higher, they're approaching that 2 million. And we're obviously trying to vet some of that out. But we very much have a long runway, as Tom just said.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Ron Feiner </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Oppenheimer &amp; Co. Inc., Research Division - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. And one follow-up. Sorry if I missed this on diopter range. We know that our recommendations change between countries and they keep getting updated and going down and down. Can you tell us what trends you're seeing generally across as you look at your markets with regard to ICL using lower diopter ranges. And are you seeing ICL use growing lower diopter ranges anywhere specifically, maybe any trends in the U.S. that you can talk about?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I don't know if it's appropriate to speak on trends. But what I will tell you is, as surgeons gain confidence and more experience in the use of EVO ICL, they naturally begin to start coming down the diopter curve. Our pivotal trial in the U.S. was, I think, the average diopter treated was a minus 7. You heard in my prepared remarks, some people have arbitrarily established a minus 8 is kind of that cutoff period when they think LASIK versus lens-based refractive surgery. And we're seeing more and more minus 3s, minus 4s, minus 5s being treated. So I think the trend is moving down,</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">11</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">but I think it's predicated on gaining the experience, seeing the confidence of happy patients, happy staff, happy surgeon usually equates to coming down the diopter curve.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from George Sellers of Stephens Inc.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Harrison Clark Parsons </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Stephens Inc., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">This is Harrison on for George. My first was about, as you see the U.S. surgeons ramp in utilization, I was wondering where specifically you see investment opportunities to drive that utilization higher? And how does that investment compare to what was needed in China during the early days of that launch?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. I wasn't here in the early days of China. But I would tell you the investment that we've put forward relative to this year is appropriate. And we're confident in the return on that investment. So I think our monies are being well utilized at this stage of where we are in the U.S. versus when we started that process in 2016 in China.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Harrison Clark Parsons </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Stephens Inc., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Got it. Yes, that makes sense. And then secondly, I was wondering, in order to convert the U.S. practices from a laser-based practice to lens-based practice, what are some of your biggest hurdles? And where have you found the most success? I know you've had a lot of success in the direct-to-consumer campaign, reaching the 1 million viewers, but anything on the surgeon awareness side we should be aware of?</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;"> </font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Again, I really don't think it's a or situation. I think it's an end situation. I think EVO ICL fits very well into a comprehensive refractive practice. It doesn't have to be, is it LASIK or is it EVO ICL? And that's why we're trying to build brand awareness, so patients are coming in inquiring about it. We're spending time educating and training surgeons. So they're comfortable offering a range of modalities to meet the needs of a practice. Clearly, the fact that you can maintain the quality of the cornea, you're not severing corneal nerves, it's removable, et cetera. patients like that story and as practices see those kinds of outcomes manifest in their patients postoperatively, their confidence level goes up, particularly at the staff level, the staff level gets more and more comfortable. The surgeon becomes even that much more comfortable, and you begin to see that inflection point. Are we there in the U.S. as we are around other markets globally? No. But are we approaching that? Yes. And I think Q2 will be stronger Q3, Q4 as we move into '24. Again, if you use our international experience, in particular, China, it was about a 2.5-year process, as I've stated. And we're about, in my mind, 6, 7 months into it. So we have about a 2-year run to really get to that inflection point. And I think we're right where we need to be and confident that we're going to be able to achieve that.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Harrison Clark Parsons </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Stephens Inc., Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Great. Congrats on the quarter.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Tom Stephan from Stifel.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">12</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas M. Stephan </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Hopping in between calls, so apologies if some of these were asked. But I wanted to start in China. Tom, if you want to maybe elaborate a bit more on kind of trends to date and what you believe the slope of the recovery there year-to-date has looked like. I guess the past 2 to 3 months maybe how did April look relative to March? And then as a follow-up to that, where do we stand in terms of the recapture of the procedures that had to be deferred in 4Q '22 and early 1Q '23? I guess if this is still ongoing, when do we think we see that backlog benefit ultimately work down, if not already? And then I have a follow-up.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. Thanks, Tom, for the question. I would say that as it relates to the backlog, the fact that we saw some really record levels of end market procedures in Q1 would suggest to me that if there was a backlog, it's being handled. We had a very strong Q1. And as stated, we remain very confident that Q2 and Q3, as we enter into the real high season in that particular market, we're very well positioned to have record quarters. So the growth has been very consistent as we previously stated, February is much stronger than January, March was much stronger than February.  We're coming off of a really solid April. We think Q2 is going to be really strong. And then obviously, the real high season kicks in July, August into early September. So we continue to feel good about where China is.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. And I'll just add, Tom, there's some sensitivity right? I just want to make sure the question is we understand it completely. It is a challenge sometimes to figure out if there was someone that put off the surgery back into Q3, Q4, when there was the no-COVID policy. But as Tom said, we're off to a very good start in Q1, record-breaking quarters. and we're off to a great start in Q2. And so in our minds, things are moving along there. And as we've said with China, it is just a very, very robust market, affirmed once again by what we said in the prepared comments of our biggest customer being here a couple of weeks ago and reiterating their focus and their investment into continuing to build that market for ICL EVO specifically.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas M. Stephan </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Stifel, Nicolaus &amp; Company, Incorporated, Research Division - Associate</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Very helpful. Makes sense. And then I want to shift to the U.S. and I'm sorry to harp on this, and Tom, you've given a lot and Patrick, a lot of really good color. But the U.S. came in a bit below for 1Q. And I think 2Q also looks at least versus our estimates, but you are encouragingly reiterating the full year '23 guidance. It does imply a pretty meaningful 2H inflection, basically doubling of sales and utilization. And I guess what I'm asking is what gives you that confidence, just given the start of the launch, maybe hasn't ramped really in that upward direction that maybe some people had hoped. And I know there's [doc side] metrics and investments you're making, but it's still a pretty significant number implied for 2H, especially with the docs train number slowing down a bit. So what gives you confidence in that 2H inflection? And then I wanted to ask about 1Q in particular. Tom, you called out, I think, a strong March, but you guided to the $5 million in late February. So I'm just curious where the disconnect is in terms of the slight miss on the 1Q guide.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Sure. Again, I appreciate the question. I think confidence comes from certainly my years of launching different technologies in ophthalmology and knowing what it takes. And I think we're doing all of the right things in terms of where we've made investments, how we're surrounding customers, and it's being well received. Our DTC spend is having an impact where we are spending dollars in targeted cities. We're seeing the kind of growth we want to see in those targeted cities. So it gives us confidence that we have the right people, we have the right programs, and we have the right processes in place that are going to bear fruit. Now I would agree with you, it puts a big number on the back half of the year. But we think we're doing the right things to be able to pull that off, and it's just going to take time. right? I think the other part of your question was, I think, relative to Q1 or Patrick...</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">13</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Rates in March. Look, it's a fair comment, Tom. And what I would tell you is we are very pleased with where we ended March in. Clearly, it was a little shy of what we had told the Street at approximately $5 million. But I know that you've heard from me, you've heard from Tom, Brian as well that when you're launching a product like this, a couple of hundred thousand dollars here or there doesn't make or break us, right? And we believe that we're continuing to do the right things. You are right about the ramp up in the second half, but we're confident in what we saw. And clearly, we've had internal discussions on this, and we came through and gave a number for Q2, which we hadn't given before, but it does imply a doubling in the second half and we're sticking with the approximately $30 million for the full year.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Jim Sidoti from Sidoti &amp; Company.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">James Philip Sidoti </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Sidoti &amp; Company, LLC - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I know you said other products are being phased out, but you did have about $20 million of revenue in the quarter. Was that higher than you thought it would be?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. A little bit higher than we thought. I think as we started talking about exiting the business, clearly, customers wanted to buy more. And so we thought this would spread out into Q2 and maybe even into Q3. But as a reminder, Jim, our guidance did not imply any other product IOL business. So it's low margin. It doesn't add a lot to the bottom line. But yes, definitely, we'll take the revenue for sure.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">James Philip Sidoti </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Sidoti &amp; Company, LLC - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Okay. And then on, if I look at the guidance updated today relative to where you were at the end of the year, the only real change is on the G&amp;A line, which looks like it's going to be up maybe $8 million or $9 million from where you thought it was going to be when you last gave guidance. Is that all related to stock-based compensation?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Primarily. We did talk about the fact that we added a couple of executives as well and some of the other infrastructure things. But yes, high majority of it is stock-based compensation, and you did hit the nail on the head. It's a little bit of an increase in G&amp;A. And I gave ourselves a little bit of (inaudible) maybe in that number for the full year, but there's not a lot of modeling changes for sure.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">James Philip Sidoti </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- Sidoti &amp; Company, LLC - Research Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Right. So other than the upside of revenue in this quarter and the change in G&amp;A, it seems like your guidance is pretty much exactly the same as it was the last time you issued it.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">14</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I would say that we upped our guidance on the revenue side, clearly, right? So we're feeling good about that. But that if you want to say that was the beat associated with in Q1, then we can debate that. But you are correct. On the rest of the model, we kept margins, OpEx, everything else very steady.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Our next question comes from Bruce Jackson of Benchmark Company.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Bruce David Jackson </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- The Benchmark Company, LLC, Research Division - Senior Equity Analyst</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">I was hoping to get some clarification on the pacing of the sales guidance. Historically, second quarter is like super strong and then it trails off for the rest of the year. This year, do you think that the U.S. is going to contribute to the revenue growth rates up sequentially for the rest of the year? Can you give us a little help on the back half of the year for the sales guidance?</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Patrick F. Williams </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - CFO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Yes. So we talked about the second quarter all in being approximately $93 million with the U.S. being $5.5 million. I think as you model that out, at least when I was looking at some of the models, you're not going to see perhaps the large or the outsized Q2 as compared to the other 3 quarters in the year, and some of that has to do with what we've been talking about quite a bit on the call now, which is the U.S. by by math has to do about $20 million in the second half. And so that's what sort of making up what I would call a more even spread of revenue to hit that [348] between Q2 to Q4.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">At this time, we have no further questions. So I will hand back the call to Tom Frinzi for any closing remarks.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thomas G. Frinzi </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">- STAAR Surgical Company - President, CEO &amp; Chairman</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thank you, operator, and thank you for joining our call today. We look forward to speaking with many of you later this week at the ASCRS meeting in San Diego and our other upcoming events in the days and weeks ahead. Thank you.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">15</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:72.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:8.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,110,186,1);padding-top:0.01in;text-indent:7.2pt;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:12.0pt;margin-top:2.0pt;font-family:Times New Roman;margin-bottom:2.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">MAY 03, 2023 / 8:30PM, STAA.OQ - Q1 2023 STAAR Surgical Co Earnings Call</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Operator</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Thank you all for joining today's call. You may now disconnect your lines.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:1.0%;"></td>
    <td style="width:98.0%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:5.75pt;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:7.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.75pt solid;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">D I S C L A I M E R</font></p></td>
    <td style="border-top:0.5pt solid;background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:5.75pt;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:7.0pt;margin-top:3.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:7.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">Refinitiv reserves the right to make changes to documents, content, or other information on this web site without obligation to notify any person of such changes.</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">In the conference calls upon which Event Transcripts are based, companies may make projections or other forward-looking statements regarding a variety of items. Such forward-looking statements are based upon current expectations and involve risks and uncertainties. Actual results may differ materially from those stated in any forward-looking statement based on a number of important factors and risks, which are more specifically identified in the companies' most recent SEC filings. Although the companies may indicate and believe that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate or incorrect and, therefore, there can be no assurance that the results contemplated in the forward-looking statements will be realized.</font></p><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">THE INFORMATION CONTAINED IN EVENT TRANSCRIPTS IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE CONFERENCE CALLS. IN NO WAY DOES REFINITIV OR THE APPLICABLE COMPANY ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY EVENT TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S CONFERENCE CALL ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;text-indent:5.75pt;word-break:break-word;white-space:pre-wrap;border-left:0.5pt solid;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="margin-left:5.75pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="border-top:0.75pt solid;padding-top:1.0pt;text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023, Refinitiv. All Rights Reserved.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;border-right:0.5pt solid;word-break:break-word;white-space:pre-wrap;vertical-align:top;border-bottom:0.5pt solid;padding-right:0.01in;text-align:right;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:3.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:6.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:55.0%;"></td>
    <td style="width:19.0%;"></td>
    <td style="width:26.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">16</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><img src="img177331332_0.jpg" alt="img177331332_0.jpg" style="width:195px;height:61px;">&#160;</p></td>
   </tr>
   <tr style="height:5.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.01in;word-break:break-word;white-space:pre-wrap;vertical-align:top;padding-right:0.01in;"><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">&#169;2023 Refinitiv. All rights reserved. Republication or redistribution of Refinitiv content, including by framing or similar means, is prohibited without the prior written</font></p><p style="text-indent:0.0pt;font-size:5.5pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(102,102,102,1);white-space:pre-wrap;font-weight:normal;font-size:5.5pt;font-family:&quot;Myriad Pro&quot;, sans-serif;min-width:fit-content;">consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img177331332_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img177331332_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !  ,P# 2(  A$! Q$!_\0
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M;P]_UZC^3U[56)<^$]&N_$UOXBFM-VJ6Z;(IMY^4<]NG<T >:_&[_D/^#/\
MK_'\UJ'XNZ5=^%M83QQH\>4GA:SU*(='5EVAC_GJ!7I^O^$=&\37-A/JEN\L
MEC)YL!61EVM^!YZ5I:EIUIJ^G3V%]"LUK.A22-NC"@#R[]GHY^'MP?\ I]D_
MD*H? W_D8_&O_7\?_0GKU/P[X9TGPKIS6&CVWV>V9S(4W%LL>^3]*CT/PGHW
MANYO;C2[3R);V3S)SO)W-DG//3J: //OVB/^2?V__7ZG\C7HWA?_ )%32?\
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MVHP%6(-NYSZUVU%;8?$5,/452D[,!%&U0/08I:**Q *YKQCX)TWQEIPM[O\
M=7$?,-RBY9/;W'M72T5I1K5*,U4INS0&%X1\.'PKX?BTHWLEX(F8K)(N" 3T
2QD\"MVBBE4J2J3<YN[>K __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>4
<FILENAME>staa-20230503_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-04T15:18:43.7582+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="staa-20230503.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>staa-20230503.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-04T15:18:43.7759+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.staar.com/20230503" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:staa="http://www.staar.com/20230503" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" namespace="http://fasb.org/us-gaap/2022"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230503_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="staa-20230503_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>staa-20230503_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2023-05-04T15:18:43.9095+00:00 -->
<!-- Copyright (c) 2023 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of each class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Name of each exchange on which registered</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol(s)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140170381701808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>May 03, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  03,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">STAAR Surgical Co<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000718937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-11634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-3797439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25651 Atlantic Ocean Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Lake Forest<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">303-7902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of each class</a></td>
<td class="text">Common<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol(s)</a></td>
<td class="text">STAA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Name of each exchange on which registered</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>staa-20230503_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="staa-20230503.xsd" xlink:type="simple"/>
    <context id="C_493298ae-fd11-4831-979d-29b516e5725e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000718937</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_64de1f4b-095f-48e3-b685-4a8f2925b0a8">0000718937</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_14d752fb-b279-4f44-bc42-953f27389b5e">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_289f05e2-2dd7-46d4-a16d-0d9ca1d67a74">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_ca1b4a79-b72f-496c-b5de-4df05f7f2f24">2023-05-03</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_9d3cfa91-fdf1-4465-898b-3a62234a8a60">STAAR Surgical Co</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_f24eb8c8-ecc4-4997-8af5-7e980d1d56cd">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_f0ec8e06-0eb0-4cc6-9c4a-51614a475d69">0-11634</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_50164d6d-eacc-4cf1-a9ac-19a4f9bcc1bf">95-3797439</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_4c6eb8b1-df80-4596-b6d3-ba7939cb738b">25651 Atlantic Ocean Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_c5ec6a8c-42df-4385-8761-384dcbad201f">Lake Forest</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_6c23b54d-804b-4774-835b-5154a090604e">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_b826b5a4-3dbd-4954-99a9-ae8484728642">92630</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_dc80706e-b08c-402b-a28a-8dbbcbbcfdb8">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_757df7b0-7edd-48a2-b533-5fab5b56cfc2">303-7902</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_ba7abf3f-3f0a-4710-bb4c-46ac842a1121">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_150c75e4-0398-4f16-b174-e9e1710e0e9f">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_c3db273f-0e51-4ec1-a868-f2de7ae48196">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_ed7443be-7fb0-4909-afca-0375a4ab6418">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_8c3d9f71-a32f-4610-b2e3-be01b91e6a54">Common</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_7e0debd2-b2f4-475a-b0d4-6abd2f65053d">STAA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_f8cdc060-094c-4890-bfbc-e58cb1a8a1a4">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_493298ae-fd11-4831-979d-29b516e5725e"
      id="F_06f37a7d-594a-4ea4-9199-a63f90cbf88a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M('BS%PQ."#[2'?'""Q)X0?A]M MH%5]0\06E7'A";B)?F2)_14MM%,S@WTU
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M:WF8,@H%9F^ [U=2FO<3NW^M?GX8_PM02P,$%     @ U("D5I^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( -2 I%8'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ U("D5GV4>Q7O    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ U("D5IE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #4
M@*16K4J0@$X$  "*$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ U("D5I^@&_"Q @  X@P   T
M         ( !D@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #4@*16EXJ[
M',     3 @  "P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4
M    " #4@*16.JJBYT !   \ @  #P              @ %7$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ U("D5B0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ U("D5F60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="staa-20230503.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="staa-20230503.htm">staa-20230503.htm</File>
    <File>staa-20230503.xsd</File>
    <File>staa-20230503_lab.xml</File>
    <File>staa-20230503_pre.xml</File>
    <File>staa-ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "staa-20230503.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "staa-20230503.htm"
     ]
    },
    "labelLink": {
     "local": [
      "staa-20230503_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "staa-20230503_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "staa-20230503.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "staa",
   "nsuri": "http://www.staar.com/20230503",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-20230503.htm",
      "contextRef": "C_493298ae-fd11-4831-979d-29b516e5725e",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "staa-20230503.htm",
      "contextRef": "C_493298ae-fd11-4831-979d-29b516e5725e",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of each class"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Name of each exchange on which registered"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol(s)"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.staar.com/20230503/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-23-017842-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-23-017842-xbrl.zip
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MZ9 "6P#^N#J3;[SHWQ=<_0=02P,$%     @ U("D5LAC+5^0!   JBD  !4
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MG\</KU%O_=%_--RGM]SQ=/<]#GGAC2IP?W4%[/_&%;#_*2O@TTV?%8/AMQM
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MEA<)]U8B]*39R?L3]<]VW]1\^4O@4DEGT2T#A+XM=3&G[H&XQ3? 1V+:EFF
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M!NZXC_IRXRIS#UW+BEK&O!4>[6Z5LVJ68;[_?+H/)W>@+)/#R'DSFR/&LX=
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ME#-X/R36PY$"*H=Q9P$PDQ0[/1A/A[I;SK7G##)$FY&[YE!1<F2X=F0&@%+
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MW6V(VSXGD0)C3\_<]C/>'CU_<RN+Z ^GZ6^-/=2CM3TK9F+!3ZXAM@4-(IC
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M>>JN[A/ZB6!\MS]8LCT0_NZNEWCT2EN>M *CW^">1R7W=M290NK$+?5T3(%
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M;OVQWL'9A?$'0CQ]?"SE.9#G_K1IUI#W+HZ2^(.B[=O.\_!!^T8-&#7@&FG
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M,RYH=&U02P$"% ,4    " #4@*16O/WCS P#  "@"0  $0
M@ &,%   <W1A82TR,#(S,#4P,RYX<V102P$"% ,4    " #4@*16!@;H%H &
M  !]0@  %0              @ ''%P  <W1A82TR,#(S,#4P,U]L86(N>&UL
M4$L! A0#%     @ U("D5LAC+5^0!   JBD  !4              ( !>AX
M '-T86$M,C R,S U,#-?<')E+GAM;%!+ 0(4 Q0    ( -2 I%9]+TGLEV0
M !ZW!  /              "  3TC  !S=&%A+65X.3E?,2YH=&U02P4&
/  4 !0!! 0   8@

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
